HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9250 | Methotrexate | Trexall | 5 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 1953 | Jan 1, 1994 | Apr 17, 2024 | No Longer Used | |
NA | Diethylstilbestrol | DES, Stilbestrol | unspecified | Hormonal Therapy | Estrogen | Yes | 1905 | 2000 | In Use | |||
J8610 | Methotrexate | Trexall | 2.5 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 1953 | Jan 1, 1995 | In Use | ||
NA | olaparib | Lynparza | 50 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2014 | In Use | |||
J8611 | Methotrexate (jylamvo) | Jylamvo | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2023 | Jun 10, 2024 | In Use | ||
J8612 | Methotrexate (xatmep) | Xatmep | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2017 | Jun 10, 2024 | In Use | ||
S0174 | Dolasetron Mesylate | Anzemet | 50 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1997 | Jan 1, 2002 | In Use | ||
NA | Pomalidomide | Pomalyst | 3 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
Q0180 | Dolasetron Mesylate | Anzemet | 100 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1997 | Apr 1, 1998 | In Use | ||
NA | Dostarlimab | Jemperli | 50mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | Yes | 2021 | In Use | |||
J7509 | Methylprednisolone Acetate | Medrol, Medrol Acetate, SOLU-medrol, Methylpred DP | 4 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1998 | Jan 1, 2000 | In Use | ||
NA | Pomalidomide | Pomalyst | 4 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
NA | Pomalidomide | Pomalyst | 1 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
NA | Pomalidomide | Pomalyst | 2 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
NA | Ponatinib | Iclusig | 15 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
NA | Ponatinib | Iclusig | 45 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 20/ 8.19 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Methyltestosterone | Android, Methitest, Testred | 10 mg | Hormonal Therapy | Androgen | Yes | 1982 | In Use | ||||
Q0167 | Dronabinol | Marinol | 2.5 mg | Ancillary Therapy | Antiemetic | CB1/CB2 | Yes | 1985 | Apr 1, 1998 | In Use | ||
Q0168 | Dronabinol | Marinol | 5 mg | Ancillary Therapy | Antiemetic | CB1/CB2 | Yes | 1985 | Apr 1, 1998 | In Use | ||
NA | Metoclopramide | Reglan | 5mg, 10mg | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Yes | 1991 | In Use | |||
NA | Midostaurin | Rydapt | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Yes | 2017 | In Use | |||
NA | Dutasteride | Avodart | 0.5mg | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Yes | 2002 | In Use | |||
NA | Duvelisib | Copiktra | 15mg, 25mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2018 | In Use | |||
S0190 | Mifepristone | Korlym, Mifeprex | 200 mg | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Yes | 2000 | Jan 1, 2001 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.